2015
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD, intergroup T. Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal Of Haematology 2015, 172: 384-391. PMID: 26577691, PMCID: PMC4794257, DOI: 10.1111/bjh.13832.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBenzamidesDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryPyridinesTreatment OutcomeConceptsTherapy-related myeloid neoplasmsMyeloid neoplasmsDe novo MDS/AMLRandomized phase 2 studyCombination of azacitidineLeukemia intergroup studyMedian overall survivalPhase 2 studyMDS/AMLSerious late effectsHistone deacetylase inhibitor entinostatAZA monotherapyCombination armNormalization rateOverall survivalIntergroup studyTreatment of cancerPoor responseLate effectsMedian numberAzacitidinePatientsSingle agentResponse rateConventional treatment
2013
Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study
Prebet T, Sun Z, Ketterling R, Greenberg P, Zeidan A, Litzow M, Gabrilove J, Erba H, Paietta E, Czader M, Gore S, Tallman M. Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. Blood 2013, 122: 2777. DOI: 10.1182/blood.v122.21.2777.2777.Peer-Reviewed Original ResearchTherapy-related myeloid neoplasmsAcute myeloid leukemiaAZA monotherapyMyeloid neoplasmsResponse rateRisk cytogeneticsCombination armMyeloid leukemiaDe novo MDS/AMLRandomized phase 2 studyECOG PS 0Higher risk MDSLeukemia intergroup studyMost prospective trialsNovo MDS patientsT-MN patientsUnfavorable-risk cytogeneticsUse of azacitidineIntermediate-risk cytogeneticsMedian overall survivalHigh-risk patientsPhase 2 studyPoor prognosis subgroupStem cell transplantPeripheral blood counts